|2.||Stomach Neoplasms (Stomach Cancer)
|3.||Colorectal Neoplasms (Colorectal Cancer)
|4.||Breast Neoplasms (Breast Cancer)
|1.||Saif, Muhammad Wasif: 25 articles (03/2014 - 03/2008)|
|2.||Imai, Kohzoh: 12 articles (11/2014 - 01/2002)|
|3.||Baldwin, Graham S: 10 articles (10/2015 - 07/2004)|
|4.||Shinomura, Yasuhisa: 9 articles (06/2012 - 07/2006)|
|5.||Yamamoto, Hiroyuki: 9 articles (06/2012 - 01/2002)|
|6.||Shulkes, Arthur: 7 articles (10/2015 - 07/2004)|
|7.||Taylor, Philip R: 7 articles (11/2011 - 09/2003)|
|8.||Wang, Jaw-Yuan: 6 articles (09/2015 - 01/2008)|
|9.||Jiang, Bo: 6 articles (11/2014 - 03/2007)|
|10.||Dawsey, Sanford M: 6 articles (01/2014 - 09/2003)|
|1.||Fluorouracil (Carac)FDA LinkGeneric
08/01/1998 - "CDDP, as a modulator for 5-FU, has already been described as a very effective treatment for gastrointestinal tract cancer. "
11/01/2010 - "In particular, combination of 5-fluorouracil (5-FU) with X-ray irradiation is effective for the treatment of some types of gastrointestinal cancers. "
02/01/1983 - "Our results suggest that the combination of MMC and 5-FU is useful in the treatment of gastrointestinal cancers in the elderly."
12/01/2002 - "A variety of data suggest benefits of 5-FU as a radiosensitizer in improving outcome of radiation therapy in a number of gastrointestinal cancers, including data indicating improved survival with this chemoradiation therapy approach. "
01/01/2010 - "In this study, we evaluated DPYD promoter methylation through quantitative methylation-specific PCR and screened DPYD for large intragenic rearrangements in peripheral blood from 45 patients with gastrointestinal cancers who developed severe 5-FU toxicity. "
|2.||irinotecan (Camptosar)FDA LinkGeneric
05/01/1993 - "CPT-11 Gastrointestinal Cancer Study Group."
02/01/2010 - "We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients. "
02/01/2010 - "Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer."
12/01/2005 - "Irinotecan was developed for gastrointestinal cancer. "
05/01/2002 - "Irinotecan (CPT-11, Camptosar) has promising single-agent activity in gastrointestinal cancers. "
|3.||oxaliplatin (Eloxatin)FDA LinkGeneric
10/01/2013 - "Oxaliplatin treatment is a mainstay of treatment for advanced gastrointestinal tract cancer, but the underlying mechanisms of acquired oxaliplatin resistance remain largely obscured. "
11/01/2015 - "Both Fluoropyrimidine and Oxaliplatin (FluOx) are the most common anticancer drugs used to treat colorectal, ovarian, and gastrointestinal cancers. "
01/01/2015 - "Effects of analgecine on oxaliplatin-induced neurotoxicity in patients with gastrointestinal cancer."
03/01/2006 - "To analyze in a pilot study the association between the pharmacokinetics of chronomodulated administered oxaliplatin and non-hematological toxicity in patients with metastatic gastrointestinal cancer. "
06/01/2003 - "Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results."
|4.||Leucovorin (Folinic Acid)FDA Link
03/01/1994 - "Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer."
02/01/2004 - "Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer."
07/01/1996 - "We evaluated the therapeutic activity of this combination in advanced colorectal cancer patients who failed the FU + folinic acid regimen, and in advanced gastrointestinal cancer situation where no standard regimen is available. "
09/01/2001 - "In Japan, multi-institutional clinical trials of l-leucovorin (l-LV), a bioactive diastereomer of leucovorin, and 5FU combination were conducted for the treatment of advanced gastrointestinal cancer with comparable results to the US/Europe data. "
02/01/1997 - "The purpose of this study was to develop a satisfactorily tolerated regimen of radiation therapy, continuous infusion 5-fluorouracil, and leucovorin in patients with locally advanced upper-abdominal gastrointestinal cancer. "
03/01/2013 - "This year at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium, the randomized phase III study presented by Uesaka et al. from Japan (Abstract #145) represents a newer paradigm of oral adjuvant S-1 chemotherapy in place of the traditional standard of care intravenous gemcitabine in terms of prolonging patients' survival. "
05/10/2012 - "Gemcitabine-releasing polymeric films for covered self-expandable metallic stent in treatment of gastrointestinal cancer."
03/01/2012 - "Several studies presented at the 2012 ASCO Gastrointestinal Cancers Symposium addressed the importance of symptom identification and management for patients with pancreatic cancer: 1) a study evaluating the correlation between patient-reported symptoms, disease burden and treatment duration in patients with advanced pancreatic cancer undergoing gemcitabine-based chemotherapy (Abstract #370); 2) a Japanese study found that patients without worsening of pain or sleep symptoms at one month of chemotherapy had higher frequency of disease control (Abstract #195); and 3) a study showed that fear of cancer recurrence is a substantial problem following resection and should be targeted (Abstract #289). "
08/01/2001 - "Thus, combining flavopiridol with gemcitabine may provide an important and novel new means of enhancing the efficacy of gemcitabine in the treatment of gastrointestinal cancers."
01/01/2010 - "In this year's ASCO Gastrointestinal Cancers Symposium, researchers presented data showing evidence of biomarkers with prognostic value (Abstracts #166, #140, and #126) and genetic polymorphisms predicting possibly efficacy of gemcitabine treatment (Abstract #166). "
|6.||Biological Markers (Surrogate Marker)IBA
09/01/2013 - "Identification of novel diagnostic, prognostic and predictive biomarkers will contribute utmost to clinical decision-making, since early diagnosis of gastrointestinal cancer and early detection of recurrence following surgery are critical for the effective treatment of patients and for a positive clinical outcome. "
08/01/2015 - "The objectives of our current study were to determine whether LDFRT can induce HRS in gastrointestinal cancer cells and to identify biomarkers of chemopotentiation by LDFRT. "
04/01/2015 - "Further trials in larger patient populations are warranted for a further evaluation of proangiogenetic factors as biomarkers in gastrointestinal cancer."
12/01/2015 - "Apoptosis-related biomarkers in patients with gastrointestinal cancer."
06/01/2015 - "Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn-5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer."
|7.||Cimetidine (Biomet)FDA LinkGeneric
10/01/2005 - "Cimetidine, one of the most popular histamine-2 receptor antagonists, has been reported to improve survival in gastrointestinal cancer patients and to activate cell-mediated immune response in surgical patients. "
04/22/2002 - "Cimetidine, a H(2) receptor antagonist, has been reported to improve survival in gastrointestinal cancer patients. "
03/01/2005 - "Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial."
01/01/2004 - "Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial."
11/01/2003 - "Cimetidine is known to suppress the growth of several tumors, including gastrointestinal cancer, in humans and animals. "
|8.||Mitomycin (Mitomycin-C)FDA LinkGeneric
06/01/1998 - "To clarify the effect on natural killer (NK) cell activity of treatment with low-dose CDDP-5-FU, we compared NK cell activity after surgery for gastrointestinal cancer in patients treated with low-dose CDDP-5-FU, a bolus dose of mitomycin C (MMC) or no anticancer drug. "
01/01/1996 - "This chapter reported the pharmacokinetics and the toxicities of mitomycin-c (MMC) when administered as a hyperthermic intraperitoneal lavage after surgical resection of advanced primary or recurrent gastrointestinal cancer. "
06/17/1968 - "Mitomycin C therapy in advanced gastrointestinal cancer."
01/01/1985 - "One hundred forty-two patients with gastrointestinal cancer were treated with combination chemotherapy containing mitomycin C. "
01/01/1990 - "These results show that intraperitoneal chemo-hyperthermia with mitomycin C is a safe and reliable treatment for peritoneal seedings in severely advanced gastrointestinal cancers and encourage us to proceed with this new therapeutic modality."
|9.||Cisplatin (Platino)FDA LinkGeneric
02/01/1997 - "Immunomodulatory effects of daily low-dose cisplatin treatment were investigated on compromised patients with advanced or recurrent gastrointestinal cancer. "
05/01/2003 - "Cisplatin is an active palliative chemotherapy agent in advanced upper gastrointestinal cancer, but it is associated with significant non-haematological toxicity. "
12/01/1986 - "Cisplatin (CDDP) was administered by intravenous drip in 3 cases of gastrointestinal cancer, and by intraperitoneal spraying in 2 other similar cases; and free CDDP and total CDDP levels in blood were determined with time. "
06/01/2013 - "S-1 in combination with cisplatin is a recommended first-line treatment for gastrointestinal cancers in Japan and has recently been approved in the EU for the treatment of advanced gastric cancer. "
05/01/1997 - "Effect of combination therapy with UFT plus cisplatin (UFTP) on the survival of mice in the experimental model for wide-spread metastasis in the peritoneal cavity of gastrointestinal cancer using colon 26 PMF-15 cells."
07/01/2015 - "Thymidylate synthase (TS) gene polymorphisms such as tandem repeat (TR) polymorphisms and single-nucleotide polymorphisms (SNPs) affect transcriptional efficiency of the TS gene and may be prognostic markers for fluoropyrimidine-based therapy in various gastrointestinal cancers. "
07/01/1999 - "Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers."
10/01/2004 - "Many studies have been published that report an association between thymidylate synthase (TS) and response to fluoropyrimidine-based chemotherapy and the overall outcome of patients with gastrointestinal cancer. "
10/01/2004 - "Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review."
05/01/2001 - "The identification of molecular markers, such as p53, thymidylate synthase, K-ras, and others, may provide an important tool for medical oncologists in defining subsets of patients with gastrointestinal cancers more suitable to benefit from chemotherapy or from experimental therapies. "
|1.||Drug Therapy (Chemotherapy)
06/01/2005 - "A new kind of method for intraperitoneal hyperthermic chemotherapy has been proved to be very effective for the therapy of gastrointestinal cancer. "
10/01/1989 - "By changing the route of administration and the timing of chemotherapy, the efficacy of drugs now routinely employed in gastrointestinal cancer can be markedly improved. "
01/01/2015 - "Preliminary observations show that endostar (once every other day) combined with chemotherapy is effective in the treatment of advanced gastrointestinal cancer, with low toxic effects, good tolerance, deserving further study."
01/01/2008 - "The results suggest that chemotherapy may be beneficial in gastrointestinal cancer patients with poor PS, as demonstrated by a certain degree of improvement in PS and survival in responders. "
04/01/1988 - "The results of chemotherapy were better in recurrent upper gastrointestinal cancer patients whose nutritional parameters were in a favorable range on admission or improved after 2 weeks of TPN."
02/01/2004 - "These promising results suggest that sentinel node navigation therapy including radiotherapy will be a new therapy for early-stage gastrointestinal malignancies in the near future, with nuclear medicine contributing to the establishment of new, less invasive therapies for gastrointestinal cancer."
11/01/2012 - "A consecutive sample of upper-gastrointestinal cancer patients admitted to the main oncology/ radiotherapy departments in the North-East of Iran were recruited into the study. "
09/01/2012 - "The purpose of this prospective multi-institutional study was to evaluate the nutritional status of patients undergoing radiotherapy (RT) for treatment of head and neck, lung, or gastrointestinal cancer. "
02/01/2011 - "This study aimed to determine whether nutritional status at radiotherapy commencement or changes in nutritional status throughout radiotherapy were associated with treatment toxicity and outcomes in gastrointestinal cancer patients. "
11/01/2014 - "Gastrointestinal cancers inherently occur amid visceral organs that are particularly sensitive to radiotherapy, creating a very narrow therapeutic window for aggressive cell kill with minimal normal tissue damage. "
12/01/2002 - "Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection."
11/01/1979 - "[Studies on parameters of immunotherapy to gastrointestinal cancer patients (author's transl)]."
12/11/2015 - "Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies. "
08/01/2015 - "Developments in immunotherapy for gastrointestinal cancer."
04/01/2008 - "Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy."
08/01/2015 - "Protocols based on the use of VK1, along with polyamine inhibitors and/or analogues, could represent a suitable alternative option for improving the efficacy of chemoprevention and treatment in future strategies for gastrointestinal cancer management. "
03/01/2013 - "Chemoprevention of gastrointestinal cancer: the reality and the dream."
06/01/2008 - "Chemoprevention of gastrointestinal cancer."
10/15/2007 - "In conclusion, our results showed that both SFN and DBM alone as well as their combination are potent natural dietary compounds for chemoprevention of gastrointestinal cancers."
03/01/2006 - "Chemoprevention in gastrointestinal cancers: current status."
|5.||Nutritional Support (Artificial Feeding)
10/01/2014 - "[Nutritional support in the treatment of patients with gastrointestinal cancer]."
08/01/2014 - "Cost-effectiveness analysis of immune-modulating nutritional support for gastrointestinal cancer patients."
10/01/2011 - "Oral nutritional support in patients with cancer of the gastrointestinal tract."
10/01/2008 - "Nutritional support during oncologic treatment of patients with gastrointestinal cancer: who could benefit?"
12/01/2007 - "Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support."